Trial · NCT03970330
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Score Area Under the Curve (AUC) | Low-Dose Naltrexone | 2461 | Standard Deviation 1445 | units on a scale*days | |
| Pain Score Area Under the Curve (AUC) | Placebo | 1338 | Standard Deviation 697 | units on a scale*days | |
| EHP-30 Score | Low-Dose Naltrexone | Baseline | 56.5 | Standard Deviation 18.3 | score on a scale |
| EHP-30 Score | Placebo | Baseline | 27.6 | Standard Deviation 19.4 | score on a scale |
| EHP-30 Score | Low-Dose Naltrexone | Week 4 | 35.5 | Standard Deviation 16.6 | score on a scale |
| EHP-30 Score | Placebo | Week 4 | 25.1 | Standard Deviation 17.1 | score on a scale |
| EHP-30 Score | Low-Dose Naltrexone | Week 8 | 34.9 | Standard Deviation 22.8 | score on a scale |
| EHP-30 Score | Placebo | Week 8 | 16.0 | Standard Deviation 8.0 | score on a scale |
| EHP-30 Score | Low-Dose Naltrexone | Week 12 | 34.1 | Standard Deviation 26.6 | score on a scale |
| EHP-30 Score | Placebo | Week 12 | 18.6 | Standard Deviation 15.8 | score on a scale |
| EHP-30 Score | Low-Dose Naltrexone | Week 16 | 35.7 | Standard Deviation 28.0 | score on a scale |
| EHP-30 Score | Placebo | Week 16 | 28.9 | Standard Deviation 23.3 | score on a scale |
| PGIC Score (Painful Periods) | Low-Dose Naltrexone | 4 weeks | 4.0 | Inter-Quartile Range 4.0 to 4.0 | units on a scale |
| PGIC Score (Painful Periods) | Placebo | 4 weeks | 6.5 | Inter-Quartile Range 5.5 to 7.0 | units on a scale |
| PGIC Score (Painful Periods) | Low-Dose Naltrexone | 8 weeks | 4.0 | Inter-Quartile Range 4.0 to 4.0 | units on a scale |
| PGIC Score (Painful Periods) | Placebo | 8 weeks | 6.5 | Inter-Quartile Range 5.5 to 7.0 | units on a scale |
| PGIC Score (Painful Periods) | Low-Dose Naltrexone | 12 weeks | 4.0 | Inter-Quartile Range 4.0 to 4.0 | units on a scale |
| PGIC Score (Painful Periods) | Placebo | 12 weeks | 6.5 | Inter-Quartile Range 6.0 to 7.0 | units on a scale |
| PGIC Score (Painful Periods) | Low-Dose Naltrexone | 16 weeks | 4.0 | Inter-Quartile Range 4.0 to 5.0 | units on a scale |
| PGIC Score (Painful Periods) | Placebo | 16 weeks | 4.5 | Inter-Quartile Range 4.0 to 5.5 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03970330/results